Lever Bio announces the extension of its Seed Round to over €9 million. The financing supports the development of immuno-oncology therapies designed to reprogram the tumor microenvironment, enabling preclinical toxicology studies and advancing multiple oncology programs toward clinical development within Lever Bio’s growing pipeline.

Lever Bio licenses LVB-006 from University of Turin to boost T cell therapy with linoleic acid, targeting solid tumors via immune metabolic reprogramming.

Lever Bio in-licenses LVB-001, a first-in-class Sema3A superagonist from Candiolo Cancer Institute to advance it towards preclinical validation and clinical translation.

Claris Ventures and Exor Ventures are joining forces in a new initiative, called Lever Bio, aimed at developing innovative drugs in collaboration with Italian universities and research centers.

Claris Ventures and Exor Ventures are joining forces in a new initiative, called Lever Bio, aimed at developing innovative drugs in collaboration with Italian universities and research centers.